Why the study?
Managing antithrombotic therapy in patients with low platelet counts or developing thrombocytopenia after ACS is challenging due to bleeding risks.
Answers are grounded in this paper and cite their sources.
The management of antiplatelet therapy in thrombocytopenic patients after ACS requires a personalized approach balancing ischemic and bleeding risks, often relying on expert consensus due to a lack of dedicated clinical trials.
The risk of cardiovascular events increases considerably after an acute coronary syndrome (ACS), particularly in the first few months. Dual antiplatelet therapy represents the mainstay of secondary prevention during this period, but is associated with a not-negligible risk of bleeding which, among other factors, is influenced by the platelet count. Thrombocytopenic patients may experience an ACS, and several patients with ACSs develop thrombocytopenia during hospitalization: the management of antithrombotic therapy in this setting represents a challenge. Here, we review the available evidence on the use of antithrombotic therapy in patients with low platelet counts after an ACS.
No takes yet. Share an insight, caveat, or question.
Paciullo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: